📣 VC round data is live. Check it out!

Neogen Valuation Multiples

Discover revenue and EBITDA valuation multiples for Neogen and similar public comparables like Dian Diagnostics Group, Fleury, Haier Biomedical, Daan Gene and more.

Neogen Overview

About Neogen

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.


Founded

1981

HQ

United States

Employees

975

Website

neogen.com

Financials (LTM)

Revenue: $859M
EBITDA: $175M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Neogen Financials

Neogen reported last 12-month revenue of $859M and EBITDA of $175M.

In the same LTM period, Neogen generated $403M in gross profit, $175M in EBITDA, and had net loss of ($47M).

Revenue (LTM)


Neogen P&L

In the most recent fiscal year, Neogen reported revenue of $895M and EBITDA of $184M.

Neogen is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 21%, and net margin of (122%).

See analyst estimates for Neogen
LTMLast FY202320242025202620272028
Revenue$859M$895M$882M$907M$873M
Gross Profit$403M$421M$440M$439M$410M
Gross Margin47%47%50%48%47%
EBITDA$175M$184M$156M($471M)($288M)
EBITDA Margin20%21%18%(52%)(33%)
EBIT Margin(7%)(0%)6%3%(2%)
Net Profit($47M)($1B)($15M)($641M)($464M)
Net Margin(6%)(122%)(2%)(71%)(53%)
Net Debt—$765M———

Financial data powered by Morningstar, Inc.

Neogen Stock Performance

Neogen has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Neogen's stock price is $8.35.

Neogen share price decreased by 11.1% in the last 30 days, and increased by 42.5% in the last year.

Neogen has an EPS (earnings per share) of $-5.02.

See more trading valuation data for Neogen
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-2.5%-11.1%-25.6%42.5%$-5.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Neogen Valuation Multiples

Neogen trades at 2.9x EV/Revenue multiple, and 14.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Neogen

EV / Revenue (LTM)


Neogen Financial Valuation Multiples

As of May 20, 2026, Neogen has market cap of $2B and EV of $2B.

Neogen has a P/E ratio of (38.3x).

LTMLast FY202320242025202620272028
EV/Revenue2.9x2.7x2.8x2.7x2.8x
EV/EBITDA14.0x13.3x15.7x(5.2x)(8.5x)
EV/EBIT(42.1x)n/m49.2x104.5x(148.6x)
EV/Gross Profit6.1x5.8x5.6x5.6x6.0x
P/E(38.3x)(1.7x)(121.0x)(2.8x)(3.9x)
EV/FCF—(52.9x)(44.8x)(41.7x)(52.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Neogen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Neogen Margins & Growth Rates

Neogen decreased revenue by 4% and EBITDA by 5% in the last fiscal year.

In the most recent fiscal year, Neogen reported gross margin of 47%, EBITDA margin of 21%, and net margin of (122%).

See estimated margins and future growth rates for Neogen

Neogen Margins

Last FY202420252026202720282029
Gross Margin47%48%47%48%
EBITDA Margin21%(52%)(33%)21%
EBIT Margin(0%)3%(2%)(1%)
Net Margin(122%)(71%)(53%)(4%)
FCF Margin(5%)(6%)(5%)—

Neogen Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(4%)3%(4%)(2%)
Gross Profit Growth(5%)(0%)(7%)(1%)
EBITDA Growth(5%)(401%)(39%)(161%)
EBIT Growth1515%(53%)(170%)(44%)
Net Profit Growth(99%)4166%(28%)(93%)
FCF Growth—7%(21%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Neogen Operational KPIs

Neogen's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.4M for the same period.

Neogen's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Neogen's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Neogen
LTMLast FY202320242025202620272028
Rule of 4019%18%———
Bessemer Rule of X18%15%———
Revenue per Employee—$0.9M———
Opex per Employee—$0.4M———
S&M Expenses to Revenue20%21%19%20%20%
G&A Expenses to Revenue29%24%23%23%27%
R&D Expenses to Revenue2%2%3%2%2%
Opex to Revenue—47%44%46%48%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Neogen Competitors

Neogen competitors include Dian Diagnostics Group, Fleury, Haier Biomedical, Daan Gene, Tecan Group, Guangzhou Wondfo Biotech, BGI Genomics, BioLife Solutions, NeoGenomics and Clinica Baviera.

Most Neogen public comparables operate across Laboratory Services.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Dian Diagnostics Group1.2x1.2x14.0x12.4x
Fleury1.4x1.4x4.9x5.5x
Haier Biomedical4.0x3.8x23.4x24.9x
Daan Gene11.0x—(18.4x)—
Tecan Group1.9x2.0x12.8x12.7x
Guangzhou Wondfo Biotech3.4x3.2x40.0x18.3x
BGI Genomics3.8x3.7x48.1x44.4x
BioLife Solutions11.0x10.3x42.8x39.6x

This data is available for Pro users. Sign up to see all Neogen competitors and their valuation data.

Start Free Trial

Neogen M&A Activity

Neogen has acquired 19 companies to date.

Last acquisition by Neogen was on December 14th 2021. Neogen acquired 3M (food safety unit) for $5B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Neogen

3M (food safety unit)
Paw Print Genetics
Delf UK
CAPInnoVet
Description
3M's Food Safety unit is a division of the Minnesota conglomerate that develops diagnostic tools and pathogen detection systems for the food industry. Its portfolio features molecular assays like Petrifilm plates and Clean-Trace hygiene monitoring swabs, adopted by processors in meat, dairy, and beverage sectors worldwide.
Paw Print Genetics is a genetic testing laboratory based in Pullman, Washington, offering DNA panels for over 350 canine inherited disorders, traits, and diversity analysis. The company serves dog breeders, owners, veterinarians, and show enthusiasts with tests for breeds like Labrador Retriever, German Shepherd, and Golden Retriever. Panels cover conditions such as degenerative myelopathy, PRA, and cystinuria, supporting responsible breeding programs across the United States.
Delf UK is a United Kingdom manufacturer of hygiene products for livestock farming and industrial cleaning. It produces teat dips, udder washes, and disinfectants under the Delpro and Farmcare brands, distributed to dairy farms across Europe. The company also supplies acid-based cleaners and foamers for food processing plants. Based in Shropshire since 1994, Delf UK adheres to EU biocidal regulations and exports to Australia.
CAPInnoVet is a U.S.-based developer of companion animal health products with a portfolio including flea and tick preventatives, heartworm treatments, and antibiotics. The company supplies affordable generic equivalents of branded pet medications through veterinary channels across North America. CAPInnoVet emphasizes pipeline expansion in dermatology and pain management therapeutics for dogs and cats.
HQ CountryUnited StatesUnited StatesUnited KingdomUnited States
HQ City
—
Spokane, WA
Liverpool
Atlanta, GA
Deal Date14 Dec 20219 Dec 20211 Dec 202120 Sep 2021
Valuation$5B$11Mundisclosed$24M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Neogen acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Neogen

When was Neogen founded?Neogen was founded in 1981.
Where is Neogen headquartered?Neogen is headquartered in United States.
How many employees does Neogen have?As of today, Neogen has over 975 employees.
Who is the CEO of Neogen?Neogen's CEO is Mikhael Nassif.
Is Neogen publicly listed?Yes, Neogen is a public company listed on Nasdaq.
What is the stock symbol of Neogen?Neogen trades under NEOG ticker.
When did Neogen go public?Neogen went public in 1989.
Who are competitors of Neogen?Neogen main competitors include Dian Diagnostics Group, Fleury, Haier Biomedical, Daan Gene, Tecan Group, Guangzhou Wondfo Biotech, BGI Genomics, BioLife Solutions, NeoGenomics, Clinica Baviera.
What is the current market cap of Neogen?Neogen's current market cap is $2B.
What is the current revenue of Neogen?Neogen's last 12 months revenue is $859M.
What is the current revenue growth of Neogen?Neogen revenue growth (NTM/LTM) is (1%).
What is the current EV/Revenue multiple of Neogen?Current revenue multiple of Neogen is 2.9x.
Is Neogen profitable?Yes, Neogen is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Neogen?Neogen's last 12 months EBITDA is $175M.
What is Neogen's EBITDA margin?Neogen's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Neogen?Current EBITDA multiple of Neogen is 14.0x.
How many companies Neogen has acquired to date?As of May 2026, Neogen has acquired 19 companies.
What was the largest acquisition by Neogen?$5B acquisition of 3M (food safety unit) on 14th December 2021 was the largest M&A Neogen has done to date.
What companies Neogen acquired?Neogen acquired 3M (food safety unit), Quat-Chem, CAPInnoVet, Preserve International, Neogen Culture Media, Chem-Tech, Rogama, Paw Print Genetics, Magiar feed, Cell BioSciences, and 9 other companies.
In how many companies Neogen has invested to date?Neogen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Neogen

Lists including Neogen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial